CoChat

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

Open access
Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., Blume, H., Klingel, R., Vogt, A · 2019 · Clinical Research in Cardiology Supplements

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Lipoprotein(a) (Lp(a)) is a genetic risk factor for cardiovascular disease (CVD) and is associated with the induction and sustaining of atherosclerotic cardiovascular diseases (ASCVD). Since 2008 Lp(a) along with progressive CVD has been approved as an indication for regular lipoprotein apheresis (LA) in Germany. The German Lipoprotein Apheresis Registry (GLAR) has been initiated to provide statistical evidence for the assessment of extracorporeal procedures to treat dyslipidemia for both LDL-cholesterol (LDL-C) and Lp(a). The GLAR now allows prospective investigations over a 5-year period about annual incidence rates of cardiovascular events. Here Lp(a) patients (LDL-C < 100 mg/dl; Lp(a) > 60 mg/dl or >120 nmol/l) showed the same reduction of major coronary (83%) and non-coronary events (63%) as had been formerly shown in the Pro(a)LiFe study. However, Lp(a) is not only an apolipoprotein(a) (apo(a)) and LDL-C containing particle, which is covalently bound to a LDL-C core by a disulphide bridge. The composition of this particle, inter alia containing oxidized phospholipids, gives pro-atherosclerotic, pro-inflammatory, and pro-thrombotic properties, inducing atherosclerotic processes mainly in the arterial wall. However, recent investigations have shown that a reduction of inflammatory settings without LDL-C or Lp(a) reduction may reduce ASCVD events. Lipoprotein apheresis (LA) could not only reduce LDL-C and Lp(a) in parallel, but also different inflammatory and coagulation parameters. In summary lipoprotein apheresis is not only anti-atherosclerotic, but also anti-inflammatory and anti-thrombotic and therefore an ideal treatment option with respect to the shown reduction of major adverse coronary events (MACE) and major adverse non-coronary events (MANCE) by reducing Lp(a) levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11789-019-00094-4

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Seven-year course of German Lipoprotein Apheresis Registry (GLAR) data with respect to a major adverse cardiac events (MACE) or b major adverse non-cardiac events (MANCE). The database interrogation used the terms Lp(a)> 60mg/dl (>120nmol/l) and LDL-C< 100mg/dl (<2.6mmol/l)
Fig. 1 Seven-year course of German Lipoprotein Apheresis Registry (GLAR) data with respect to a major adverse cardiac events (MACE) or b major adverse non-cardiac events (MANCE). The database interrogation used the terms Lp(a)> 60mg/dl (>120nmol/l) and LDL-C< 100mg/dl (<2.6mmol/l)CC-BY · From the PDF
Fig. 2 The complex effect of lipoprotein apheresis (LA) on the atherogenicity of Lp(a), which was classified in 3 categories: pro-inflammatory, pro-thrombotic, and therefore pro-atherogenic [2, 41-44]. The given parameters are only examples, the influence of LA on blood components is far-ranging
Fig. 2 The complex effect of lipoprotein apheresis (LA) on the atherogenicity of Lp(a), which was classified in 3 categories: pro-inflammatory, pro-thrombotic, and therefore pro-atherogenic [2, 41-44]. The given parameters are only examples, the influence of LA on blood components is far-rangingCC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 40

Metadata

Authors
Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., Blume, H., Klingel, R., & Vogt, A.
Affiliations
  • Nephrologisches Zentrum Goettingen (DE)
  • Landesamt für Gesundheit und Soziales (DE)
  • University Hospital Carl Gustav Carus (DE)
  • Agaplesion Markus Hospital (DE)
  • Apherese Forschungsinstitut (DE)
  • Ludwig-Maximilians-Universität München (DE)
Corresponding author
Schettler, V. J. J.
Venue
Clinical Research in Cardiology Supplements
Published
2019-03-05
Volume
14
Issue
S1
Pages
33-38
ISSN
  • 1861-0706 (ISSN-L)
  • 1861-0714
OpenAlex
W2922236150
Cited by
37
References
44
Citations by year
2026: 4 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 2 · 2019: 3
FWCI
3.85
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Clinical Research in Cardiology Supplements (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
lipoprotein apheresis, lipoprotein(a), cardiovascular disease, atherosclerotic cardiovascular disease, major adverse coronary events, dyslipidemia, apolipoprotein(a), inflammation, coagulation, oxidized phospholipids, LDL cholesterol
MeSH terms
Blood Component Removal, Cardiovascular Diseases, Germany, Humans, Cholesterol, LDL, Registries, Risk Factors, Lipoprotein(a), Genetic Predisposition to Disease, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. https://app.cochat.ai/papers/10.1007/s11789-019-00094-4
The paper
Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., Blume, H., Klingel, R., & Vogt, A. (2019). Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clinical Research in Cardiology Supplements. https://doi.org/10.1007/s11789-019-00094-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.